BSc2118

BSc2118 is a **novel, small-molecule proteasome inhibitor** developed for anticancer therapy. It demonstrates significant cytotoxic and pro-apoptotic activity in multiple myeloma cell lines and primary myeloma cells, leading to cell cycle arrest (G2-M), induction of apoptosis, inhibition of intracellular proteasome activity, increased intracellular p21, and inhibition of NF-κB activation. BSc2118 also exhibits neuroprotective effects in preclinical models of cerebral ischemia (stroke) by reducing brain injury, stabilizing the blood-brain barrier, decreasing matrix metalloproteinase 9 activity, enhancing angioneurogenesis, and increasing hypoxia-inducible factor 1-alpha (HIF1A) expression. It shows relatively low toxicity to normal peripheral blood mononuclear cells and is considered a promising agent in oncology and neuroprotection studies[1][3][5][7][8][9].